샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785139

OTC 결핍증 치료 시장 : 성장, 전망, 경쟁 분석(2025-2033년)

Ornithine Transcarbamylase Deficiency Treatment Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
발행일: | 리서치사: Acute Market Reports | 페이지 정보: 영문 173 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 OTC 결핍증 치료 시장은 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 4.1%를 나타낼 것으로 예측됩니다. 성장의 원동력은 우레아 사이클 이상증에 대한 인식 증가, 신생아 스크리닝 프로그램 증가, 생존율 및 QOL을 개선하는 표적 요법의 개발입니다. OTC 결핍증(OTCD)은 드문 유전성 대사 질환이며, 약물 치료와 식사 개입에 의한 평생에 걸친 관리가 필요하게 되는 경우가 많습니다. 시장은 암모니아 소거제의 기술 혁신, 의료 식품에 대한 접근의 확대, 희귀질환의 조기 진단 및 치료를 장려하는 정부의 지원 수단에 의해 지원됩니다.

시장 성장 촉진요인

진단률 상승 및 조기 개입 프로그램

유전자 검사의 진보와 신생아 스크리닝 프로그램의 확대로 OTCD의 조기 발견률이 현저히 향상되었습니다. 조기 개입은 높은 암모니아 혈증 관련 합병증을 피하는 데 매우 중요하며 진단되지 않은 경우 치명적일 수 있습니다. 부페닐이나 라빅티(암모니아 소거제)와 같은 의약품의 기술 혁신은 더 나은 질병 관리를 가능하게 하고 치료 제품에 대한 수요가 증가하고 있습니다. 게다가, 의료 전문가의 의식의 향상과 환자 옹호 활동의 개선이, 유증상자나 보균자의 동정 향상에 기여하고 있어, 그에 의해 진단 대상 인구가 확대하고 있습니다.

전문 식단 관리 및 의료 영양 솔루션 증가

식사 관리는 여전히 OTC 결핍증 치료의 요점이며, 저단백 아미노산 조절식이 표준 치료가 되고 있습니다. 시장은 Nutricia, Mead Johnson, Nestle과 같은 기업이 제공하는 고품질 영양 보조 식품 및 의료 영양 제품에 대한 수요가 증가하고 있습니다. 이 제품은 약물 치료를 보완하고 신진 대사 조절을 개선하며 신경학적 결과를 지원합니다. 개인화된 다이어트 프로토콜의 출현과 희귀 대사 질환에서 임상 영양사에 대한 접근성이 증가함에 따라 전 세계적으로 치료 어드레싱과 환자 결과가 향상되었습니다.

시장 성장 억제요인

제한된 환자 수와 높은 치료비

OTCD는 매우 희귀질환이기 때문에 환자 수가 적고, 특히 유전자 스크리닝이 발달되지 않은 저소득 지역에서는 시장이 제한적입니다. 라빅티나 암모널과 같은 고가의 치료비는 가정과 의료 시스템에 경제적인 과제가 됩니다. 희귀의약품 및 의료용 식품에 대한 상환의 장애물과 제한된 보험 적용이 특히 신흥국 시장에서의 액세스를 더욱 제약하고 있습니다. 게다가 희귀질환의 긴 규제 일정과 복잡한 시험 설계는 신제품 승인을 제한하고 시장 역동성을 낮추고 있습니다.

제품별 시장 구분

OTC 결핍증 치료 시장은 부페닐, 라빅티, 암모널, 영양 보충제 및 기타 제품으로 구분됩니다. 2024년에는 라빅티가 뛰어난 효능, 1일 1회 투여의 편의성, 과거의 치료제에 비해 양호한 부작용 프로파일로 시장을 선도했습니다. 암모널은 주로 병원 환경에서 급성 고암모니아혈증 에피소드에 사용됩니다. 필수 아미노산과 무질소 제제를 포함한 영양 보충제는 특히 소아 환자와 표현형이 가벼운 환자를 중심으로 시장 규모가 확대되고 있습니다. 예측 기간 동안 영양 보충제는 환자의 의식이 증가하고 임상에서 광범위한 채택으로 꾸준한 성장이 예상됩니다.

투여 경로별 시장 구분

투여 경로에 따라 시장은 경구 투여와 정맥 내 투여로 분류됩니다. 2024년에는 라빅티, 부페닐, 영양 보충제가 만성적으로 경구 투여되기 때문에 경구 투여가 가장 큰 점유율을 차지했습니다. 정맥내 투여는 대사성 위기시 암모널을 사용하는 긴급 개입으로 제한됩니다. 2025년부터 2033년까지는 환자 중심의 의약품 개발, 컴플라이언스 강화, 재택 투여의 편의성 등에 힘입어 경구 투여 부문이 우위를 유지할 것으로 예측됩니다.

지역별 동향

북미는 강력한 진단 인프라, 희귀 질병 의약품에 대한 유리한 상환, Ultragenyx 및 Acer Therapeutics와 같은 주요 제약 회사의 존재로 2024년 OTC 결핍증 치료 시장을 견인했습니다. 이어 신생아 스크리닝 프로그램과 희소질환 치료 네트워크의 일원화를 확립하고 있는 구미 국가들이 크게 공헌하고 있습니다. 아시아태평양은 유전자 검사에 대한 투자 증가, 대사성 질환에 대한 의식 증가, 세계 영양 브랜드와의 제휴 증가 등에 힘입어 예측 기간 동안 가장 빠른 CAGR을 나타낼 것으로 예측됩니다. 그러나 라틴아메리카와 중동 및 아프리카에서는 의료 자금이 제한되어 있기 때문에 희귀질환 치료에 대한 관심이 높아지고 있음에도 불구하고 시장 섭취가 억제 될 수 있습니다.

경쟁 동향

2024년 경쟁 구도는 제약 제조업체, 생명공학 혁신자, 의료 영양 제산업체가 혼합되어 있었습니다. 울트라제닉스 퍼머슈티칼과 에이서 세라퓰틱스는 타겟 좁은 OTC 결핍증 치료제의 유명한 개발 기업으로 환자 중심의 처방과 접근 확대를 위한 노력에 주력하고 있습니다. Bausch Health와 Arcturus Therapeutics는 mRNA 기반 치료 전략과 새로운 전달 메커니즘을 모색합니다. 뉴트리시아(다논), 미드 존슨(레킷 벤키저), 네슬레 등의 영양 회사는 식단 개입을 관리하는데 중요한 역할을 하고 있습니다. Abbott Laboratories와 OrphanPacific은 신진 대사 관리 포트폴리오를 확대하고 있습니다. 주요 경쟁의 우선 과제는 약물의 선호도 개선, 소아 적응 확대, 세계 유통 강화, 차세대 치료 임상시험 추진 등입니다.

목차

제1장 서문

  • 분석 내용
    • 분석의 목적
    • 대상자
    • 주요 제공 내용
  • 시장 구분
  • 분석 방법
    • 1단계 : 2차 조사
    • 2단계 : 1차 조사
    • 3단계 : 지식인 리뷰
    • 전제조건
    • 채용한 접근

제2장 주요 요약

제3장 OTC 결핍증 치료 시장 : 경쟁 분석

  • 주요 제산업체의 시장 포지셔닝
  • 제산업체가 채용한 전략

제4장 OTC 결핍증 치료 시장 : 매크로 분석과 시장 역학

  • 서론
  • 세계의 OTC 결핍증 치료 시장(금액 기준, 2023-2033년)
  • 시장 역학
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 주요 과제
    • 주요 기회
  • 성장 촉진요인과 억제요인의 영향 분석
  • Porter's Five Forces 모델
    • 공급자 파워
    • 바이어의 힘
    • 대체품의 위협
    • 신규 참가업체의 위협
    • 경쟁 기업 간 경쟁 관계
  • PESTEL 분석
    • 정치적 상황
    • 경제적 상황
    • 기술적 상황
    • 법적 상황
    • 사회적 상황

제5장 OTC 결핍증 치료 시장 : 제품별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 구분
    • 부페닐
    • 라빅티
    • 암모눌
    • 영양보조식품
    • 기타 제품

제6장 OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 구분
    • 구강
    • 정맥 주사

제7장 OTC 결핍증 치료 시장 : 연령층별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 구분
    • 소아
    • 성인

제8장 OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)

  • 시장 개요
  • 성장·수익 분석 : 2024년 vs 2033년
  • 시장 구분
    • 병원 약국
    • 소매 약국
    • 온라인 약국

제9장 북미의 OTC 결핍증 치료 시장(2023-2033년)

  • 시장 개요
  • OTC 결핍증 치료 시장 : 제품별(2023-2033년)
  • OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)
  • OTC 결핍증 치료 시장 : 연령층별(2023-2033년)
  • OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)
  • OTC 결핍증 치료 시장 : 지역별(2023-2033년)
    • 북미
      • 미국
      • 캐나다
      • 기타 북미

제10장 영국 및 유럽 연합의 OTC 결핍증 치료 시장(2023-2033년)

  • 시장 개요
  • OTC 결핍증 치료 시장 : 제품별(2023-2033년)
  • OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)
  • OTC 결핍증 치료 시장 : 연령층별(2023-2033년)
  • OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)
  • OTC 결핍증 치료 시장 : 지역별(2023-2033년)
    • 영국 및 유럽 연합
      • 영국
      • 독일
      • 스페인
      • 이탈리아
      • 프랑스
      • 기타 유럽

제11장 아시아태평양의 OTC 결핍증 치료 시장(2023-2033년)

  • 시장 개요
  • OTC 결핍증 치료 시장 : 제품별(2023-2033년)
  • OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)
  • OTC 결핍증 치료 시장 : 연령층별(2023-2033년)
  • OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)
  • OTC 결핍증 치료 시장 : 지역별(2023-2033년)
    • 아시아태평양
      • 중국
      • 일본
      • 인도
      • 호주
      • 한국
      • 기타 아시아태평양

제12장 라틴아메리카의 OTC 결핍증 치료 시장(2023-2033년)

  • 시장 개요
  • OTC 결핍증 치료 시장 : 제품별(2023-2033년)
  • OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)
  • OTC 결핍증 치료 시장 : 연령층별(2023-2033년)
  • OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)
  • OTC 결핍증 치료 시장 : 지역별(2023-2033년)
    • 라틴아메리카
      • 브라질
      • 멕시코
      • 기타 라틴아메리카

제13장 중동 및 아프리카의 OTC 결핍증 치료 시장(2023-2033년)

  • 시장 개요
  • OTC 결핍증 치료 시장 : 제품별(2023-2033년)
  • OTC 결핍증 치료 시장 : 투여 경로별(2023-2033년)
  • OTC 결핍증 치료 시장 : 연령층별(2023-2033년)
  • OTC 결핍증 치료 시장 : 유통 채널별(2023-2033년)
  • OTC 결핍증 치료 시장 : 지역별(2023-2033년)
    • 중동 및 아프리카
      • 걸프 협력 회의(GCC) 국가
      • 아프리카
      • 기타 중동 및 아프리카

제14장 기업 프로파일

  • Abbott Laboratories
  • Acer Therapeutics
  • Amgen
  • Arcturus Therapeutics
  • Bausch Health Companies
  • Nestle
  • OrphanPacific
  • 기타 주요 기업
KTH 25.08.14

The global ornithine transcarbamylase deficiency (OTCD) treatment market is projected to grow at a CAGR of 4.1% from 2025 to 2033. Growth is driven by increasing awareness of urea cycle disorders, rising newborn screening programs, and the development of targeted therapies that improve survival and quality of life. OTCD, a rare genetic metabolic disorder, often requires lifelong management through pharmacological treatment and dietary interventions. The market is supported by innovations in ammonia scavenging agents, expanded access to medical foods, and supportive government initiatives encouraging early diagnosis and treatment of rare diseases.

Market Drivers

Increased Diagnosis Rates and Early Intervention Programs

Advancements in genetic testing and the expansion of newborn screening programs have significantly improved early detection rates of OTCD. Early intervention is critical in avoiding hyperammonemia-related complications, which can be fatal in undiagnosed cases. Pharmaceutical innovations such as Buphenyl and Ravicti (ammonia-scavenging agents) have enabled better disease management, leading to higher demand for therapeutic products. Furthermore, increasing healthcare professional awareness and improved patient advocacy are contributing to better identification of symptomatic and carrier individuals, thereby expanding the diagnosed population base.

Rise in Specialized Dietary Management and Medical Nutrition Solutions

Dietary management remains a cornerstone in OTCD treatment, with low-protein, amino acid-modified diets being standard care. The market has witnessed increasing demand for high-quality dietary supplements and medical nutrition products offered by companies such as Nutricia, Mead Johnson, and Nestle. These products complement pharmacological therapy, improve metabolic control, and support neurological outcomes. The emergence of personalized dietary protocols and growing access to clinical dieticians in rare metabolic disorders is enhancing treatment adherence and patient outcomes globally.

Market Restraint

Limited Patient Population and High Treatment Costs

As OTCD is an ultra-rare condition, the market is limited by a small patient population base, particularly in low-income regions where genetic screening is underdeveloped. The high cost of therapies like Ravicti and Ammonul poses affordability challenges for families and healthcare systems. Reimbursement hurdles and limited insurance coverage for orphan drugs and medical foods further constrain access, especially in developing markets. Additionally, long regulatory timelines and complex trial designs in rare diseases limit new product approvals, reducing market dynamism.

Market Segmentation by Product

The OTCD treatment market is segmented into Buphenyl, Ravicti, Ammonul, Dietary Supplements, and Other Products. In 2024, Ravicti led the market due to its superior efficacy, once-daily dosing convenience, and favorable side-effect profile compared to older therapies. Ammonul is primarily used in acute hyperammonemic episodes in hospital settings. Dietary supplements, including essential amino acids and nitrogen-free formulas, represent a growing market segment, particularly among pediatric patients and individuals with milder phenotypes. Over the forecast period, dietary products are expected to witness steady growth due to increasing patient awareness and broader clinical adoption.

Market Segmentation by Route of Administration

Based on route of administration, the market is categorized into Oral and Intravenous. In 2024, oral administration accounted for the largest share due to the widespread use of Ravicti, Buphenyl, and dietary supplements taken orally on a chronic basis. Intravenous administration is largely confined to emergency interventions using Ammonul during metabolic crises. From 2025 to 2033, the oral segment is expected to maintain dominance, supported by patient-centric drug development, enhanced compliance, and the convenience of at-home administration.

Geographic Trends

North America led the OTCD treatment market in 2024, driven by strong diagnostic infrastructure, favorable reimbursement for orphan drugs, and the presence of key pharmaceutical players like Ultragenyx and Acer Therapeutics. Europe followed, with significant contributions from Western countries that have established newborn screening programs and centralized rare disease treatment networks. The Asia Pacific region is expected to witness the fastest CAGR during the forecast period, bolstered by rising investments in genetic testing, growing awareness of metabolic disorders, and increasing partnerships with global nutrition brands. However, limited healthcare funding in Latin America and the Middle East & Africa may restrain market uptake despite growing interest in rare disease care.

Competitive Trends

The competitive landscape in 2024 featured a mix of pharmaceutical manufacturers, biotech innovators, and medical nutrition providers. Ultragenyx Pharmaceutical and Acer Therapeutics were among the prominent developers of targeted OTCD therapies, focusing on patient-centric formulations and expanded access initiatives. Bausch Health and Arcturus Therapeutics are exploring mRNA-based treatment strategies and novel delivery mechanisms. Nutrition companies such as Nutricia (Danone), Mead Johnson (Reckitt Benckiser), and Nestle play a critical role in managing dietary interventions. Abbott Laboratories and OrphanPacific are expanding portfolios in metabolic care. Key competitive priorities include improving drug palatability, expanding pediatric indications, enhancing global distribution, and advancing clinical trials for next-generation treatments.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Ornithine Transcarbamylase Deficiency Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Ornithine Transcarbamylase Deficiency Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

  • Product
  • Buphenyl
  • Ravicti
  • Ammonul
  • Dietary supplements
  • Other products
  • Route of Administration
  • Oral
  • Intravenous
  • Age Group
  • Pediatrics
  • Adults
  • Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Ornithine Transcarbamylase Deficiency Treatment market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Ornithine Transcarbamylase Deficiency Treatment market?
  • Which is the largest regional market for Ornithine Transcarbamylase Deficiency Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Ornithine Transcarbamylase Deficiency Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Ornithine Transcarbamylase Deficiency Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Ornithine Transcarbamylase Deficiency Treatment Market
  • 2.2. Global Ornithine Transcarbamylase Deficiency Treatment Market, By Product, 2024 (US$ Million)
  • 2.3. Global Ornithine Transcarbamylase Deficiency Treatment Market, By Route of Administration, 2024 (US$ Million)
  • 2.4. Global Ornithine Transcarbamylase Deficiency Treatment Market, By Age Group, 2024 (US$ Million)
  • 2.5. Global Ornithine Transcarbamylase Deficiency Treatment Market, By Distribution Channel, 2024 (US$ Million)
  • 2.6. Global Ornithine Transcarbamylase Deficiency Treatment Market, By Geography, 2024 (US$ Million)
  • 2.7. Attractive Investment Proposition by Geography, 2024

3. Ornithine Transcarbamylase Deficiency Treatment Market: Competitive Analysis

  • 3.1. Market Positioning of Key Ornithine Transcarbamylase Deficiency Treatment Market Vendors
  • 3.2. Strategies Adopted by Ornithine Transcarbamylase Deficiency Treatment Market Vendors

4. Ornithine Transcarbamylase Deficiency Treatment Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Ornithine Transcarbamylase Deficiency Treatment Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. Porter's Five Force Model
    • 4.5.1. Supplier Power
    • 4.5.2. Buyer Power
    • 4.5.3. Threat Of Substitutes
    • 4.5.4. Threat Of New Entrants
    • 4.5.5. Competitive Rivalry
  • 4.6. PESTEL Analysis
    • 4.6.1. Political Landscape
    • 4.6.2. Economic Landscape
    • 4.6.3. Technology Landscape
    • 4.6.4. Legal Landscape
    • 4.6.5. Social Landscape

5. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Buphenyl
    • 5.3.2. Ravicti
    • 5.3.3. Ammonul
    • 5.3.4. Dietary supplements
    • 5.3.5. Other products

6. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Oral
    • 6.3.2. Intravenous

7. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 7.3. Market Segmentation
    • 7.3.1. Pediatrics
    • 7.3.2. Adults

8. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 8.3. Market Segmentation
    • 8.3.1. Hospital pharmacies
    • 8.3.2. Retail pharmacies
    • 8.3.3. Online pharmacies

9. North America Ornithine Transcarbamylase Deficiency Treatment Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
  • 9.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 9.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
  • 9.5. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 9.6. Ornithine Transcarbamylase Deficiency Treatment Market: By Region, 2023-2033, USD (Million)
    • 9.6.1. North America
      • 9.6.1.1. U.S.
        • 9.6.1.1.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 9.6.1.1.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.1.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 9.6.1.1.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.6.1.2. Canada
        • 9.6.1.2.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 9.6.1.2.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.2.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 9.6.1.2.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 9.6.1.3. Rest of North America
        • 9.6.1.3.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 9.6.1.3.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 9.6.1.3.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 9.6.1.3.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

10. UK and European Union Ornithine Transcarbamylase Deficiency Treatment Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
  • 10.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 10.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
  • 10.5. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 10.6. Ornithine Transcarbamylase Deficiency Treatment Market: By Region, 2023-2033, USD (Million)
    • 10.6.1. UK and European Union
      • 10.6.1.1. UK
        • 10.6.1.1.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.1.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.1.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.1.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.2. Germany
        • 10.6.1.2.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.2.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.2.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.2.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.3. Spain
        • 10.6.1.3.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.3.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.3.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.3.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.4. Italy
        • 10.6.1.4.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.4.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.4.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.4.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.5. France
        • 10.6.1.5.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.5.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.5.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.5.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 10.6.1.6. Rest of Europe
        • 10.6.1.6.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 10.6.1.6.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 10.6.1.6.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 10.6.1.6.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

11. Asia Pacific Ornithine Transcarbamylase Deficiency Treatment Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
  • 11.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 11.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
  • 11.5. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 11.6. Ornithine Transcarbamylase Deficiency Treatment Market: By Region, 2023-2033, USD (Million)
    • 11.6.1. Asia Pacific
      • 11.6.1.1. China
        • 11.6.1.1.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.1.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.1.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.1.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.2. Japan
        • 11.6.1.2.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.2.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.2.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.2.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.3. India
        • 11.6.1.3.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.3.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.3.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.3.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.4. Australia
        • 11.6.1.4.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.4.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.4.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.4.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.5. South Korea
        • 11.6.1.5.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.5.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.5.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.5.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 11.6.1.6. Rest of Asia Pacific
        • 11.6.1.6.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 11.6.1.6.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 11.6.1.6.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 11.6.1.6.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

12. Latin America Ornithine Transcarbamylase Deficiency Treatment Market, 2023-2033, USD (Million)

  • 12.1. Market Overview
  • 12.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
  • 12.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 12.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
  • 12.5. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 12.6. Ornithine Transcarbamylase Deficiency Treatment Market: By Region, 2023-2033, USD (Million)
    • 12.6.1. Latin America
      • 12.6.1.1. Brazil
        • 12.6.1.1.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 12.6.1.1.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.1.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 12.6.1.1.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.6.1.2. Mexico
        • 12.6.1.2.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 12.6.1.2.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.2.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 12.6.1.2.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 12.6.1.3. Rest of Latin America
        • 12.6.1.3.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 12.6.1.3.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 12.6.1.3.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 12.6.1.3.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

13. Middle East and Africa Ornithine Transcarbamylase Deficiency Treatment Market, 2023-2033, USD (Million)

  • 13.1. Market Overview
  • 13.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
  • 13.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
  • 13.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
  • 13.5. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
  • 13.6. Ornithine Transcarbamylase Deficiency Treatment Market: By Region, 2023-2033, USD (Million)
    • 13.6.1. Middle East and Africa
      • 13.6.1.1. GCC
        • 13.6.1.1.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 13.6.1.1.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.1.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 13.6.1.1.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.6.1.2. Africa
        • 13.6.1.2.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 13.6.1.2.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.2.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 13.6.1.2.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)
      • 13.6.1.3. Rest of Middle East and Africa
        • 13.6.1.3.1. Ornithine Transcarbamylase Deficiency Treatment Market: By Product, 2023-2033, USD (Million)
        • 13.6.1.3.2. Ornithine Transcarbamylase Deficiency Treatment Market: By Route of Administration, 2023-2033, USD (Million)
        • 13.6.1.3.3. Ornithine Transcarbamylase Deficiency Treatment Market: By Age Group, 2023-2033, USD (Million)
        • 13.6.1.3.4. Ornithine Transcarbamylase Deficiency Treatment Market: By Distribution Channel, 2023-2033, USD (Million)

14. Company Profile

  • 14.1. Abbott Laboratories
  • 14.2. Acer Therapeutics
  • 14.3. Amgen
  • 14.4. Arcturus Therapeutics
  • 14.5. Bausch Health Companies
  • 14.6. Nestle
  • 14.7. OrphanPacific
  • 14.8. Other Notable Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제